Oncotarget

Addendum:

Addendum: Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report

PDF  |  How to cite

Oncotarget. 2023; 14:438-438. https://doi.org/10.18632/oncotarget.28428

Metrics: PDF 600 views  |   ?  

Mayank Rao1, Meenakshi Bhattacharjee2, Scott Shepard3 and Sigmund Hsu1

1The Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
2Department of Pathology and Laboratory Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
3Department of Neurosurgery, Temple University School of Medicine, Philadelphia, PA 19140, USA

Published: May 10, 2023

Copyright: © 2023 Rao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Informed patient consent was obtained.

Original article: Oncotarget. 2019; 10:6038-6042. DOI: https://doi.org/10.18632/oncotarget.27203.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28428